九洲药业
(603456)
| 流通市值：126.21亿 | | | 总市值：126.21亿 |
| 流通股本：8.89亿 | | | 总股本：8.89亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,490,269,186.29 | 5,160,584,725.38 | 3,965,261,223.17 | 2,764,279,820.31 |
| 营业收入 | 1,490,269,186.29 | 5,160,584,725.38 | 3,965,261,223.17 | 2,764,279,820.31 |
| 二、营业总成本 | 1,154,593,465.07 | 4,227,810,994.3 | 3,190,787,304.91 | 2,176,923,770.53 |
| 营业成本 | 932,606,998.63 | 3,417,168,674.67 | 2,587,368,120.12 | 1,790,907,120.13 |
| 税金及附加 | 20,520,982.63 | 55,954,062.32 | 40,089,787.46 | 31,781,297.47 |
| 销售费用 | 22,944,744.54 | 99,897,934.73 | 72,344,977.48 | 43,892,002.85 |
| 管理费用 | 115,291,574.36 | 417,726,997.48 | 300,560,133.5 | 197,947,419.63 |
| 研发费用 | 67,680,193.57 | 314,912,328.62 | 240,137,612.13 | 160,008,049.72 |
| 财务费用 | -4,451,028.66 | -77,849,003.52 | -49,713,325.78 | -47,612,119.27 |
| 其中:利息费用 | 2,381,863.17 | 19,377,418.23 | 16,307,011.53 | 14,233,916.01 |
| 其中:利息收入 | 6,122,453.87 | 86,063,888.8 | 72,828,114.9 | 57,715,485.93 |
| 加:投资收益 | -982,573.49 | -8,132,266.51 | -4,629,630.62 | -5,328,237.59 |
| 资产处置收益 | -221,826.43 | -3,156,554.9 | -2,099,975.26 | -2,811,070.01 |
| 资产减值损失(新) | -27,202,298.57 | -218,481,518.23 | -38,630,224.5 | -26,268,486.77 |
| 信用减值损失(新) | -2,563,081.82 | -16,628,744.16 | -12,933,546.38 | -21,984,102.86 |
| 其他收益 | 6,703,397.46 | 45,811,806.57 | 30,919,535.52 | 23,710,282.3 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 311,409,338.37 | 732,186,453.85 | 747,100,077.02 | 554,674,434.85 |
| 加:营业外收入 | 175,458.03 | 1,781,303.01 | 651,393.57 | 580,391.26 |
| 减:营业外支出 | 1,064,448.05 | 3,365,334.85 | 1,041,692.65 | 384,163.07 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 310,520,348.35 | 730,602,422.01 | 746,709,777.94 | 554,870,663.04 |
| 减:所得税费用 | 60,622,057.31 | 123,534,905.18 | 113,857,286.13 | 79,257,105.79 |
| 六、净利润 | 249,898,291.04 | 607,067,516.83 | 632,852,491.81 | 475,613,557.25 |
| 持续经营净利润 | 249,898,291.04 | 607,067,516.83 | 632,852,491.81 | 475,613,557.25 |
| 归属于母公司股东的净利润 | 250,202,958.78 | 606,096,350.9 | 630,876,705.82 | 474,988,640.43 |
| 少数股东损益 | -304,667.74 | 971,165.93 | 1,975,785.99 | 624,916.82 |
| (一)基本每股收益 | 0.28 | 0.68 | 0.7 | 0.53 |
| (二)稀释每股收益 | 0.28 | 0.68 | 0.7 | 0.53 |
| 八、其他综合收益 | 3,364,061.56 | 6,222,572.26 | -3,871,050.78 | 1,710,782.56 |
| 归属于母公司股东的其他综合收益 | 3,364,061.56 | 6,222,572.26 | -3,871,050.78 | 1,710,782.56 |
| 九、综合收益总额 | 253,262,352.6 | 613,290,089.09 | 628,981,441.03 | 477,324,339.81 |
| 归属于母公司股东的综合收益总额 | 253,567,020.34 | 612,318,923.16 | 627,005,655.04 | 476,699,422.99 |
| 归属于少数股东的综合收益总额 | -304,667.74 | 971,165.93 | 1,975,785.99 | 624,916.82 |
| 公告日期 | 2025-04-15 | 2025-04-11 | 2024-10-25 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |